Foghorn Therapeutics (FHTX) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Foghorn Therapeutics (FHTX) overview

Foghorn Therapeutics (FHTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 30.9m and operating profit of USD -86.4m; the year-end share price was 5.40 USD and market capitalisation was USD 306m. Foghorn Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Foghorn Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -109mFY 2025
Share price5.40 USDFY 2025 year end
RevenueUSD 30.9mFY 2025
Operating profitUSD -86.4mFY 2025
Net earningsUSD -74.3mFY 2025
Market capitalisationUSD 306mFY 2025 year end

About Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company developing medicines that target the chromatin regulatory system to address abnormal gene expression. Its Gene Traffic Control platform supports the identification and validation of drug targets. The company’s programs include small-molecule approaches such as protein degraders, enzymatic inhibitors, and transcription factor disruptors, with a focus on oncology and potential applications in other disease areas.

Generate the Foghorn Therapeutics report

Foghorn Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Foghorn Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Foghorn Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.